Hot Features
Premium
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Nuvalent Inc | NUVL | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 70.88 | 05:32:50 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 70.88 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 38.14 - 89.39 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 70.88 | USD |
Nuvalent Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 4.54B | 64.07M | - | 0 | -126.22M | -1.97 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Nuvalent News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NUVL Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 66.38 | 74.50 | 64.67 | 70.00 | 370,374 | 4.50 | 6.78% |
| 1 Month | 63.00 | 74.79 | 62.2335 | 68.51 | 384,188 | 7.88 | 12.51% |
| 3 Months | 87.33 | 89.39 | 61.795 | 73.42 | 491,106 | -16.45 | -18.84% |
| 6 Months | 59.94 | 89.39 | 58.80 | 74.09 | 460,089 | 10.94 | 18.25% |
| 1 Year | 39.38 | 89.39 | 38.14 | 61.53 | 484,680 | 31.50 | 79.99% |
| 3 Years | 18.10 | 89.39 | 7.09 | 45.20 | 307,437 | 52.78 | 291.60% |
| 5 Years | 18.10 | 89.39 | 7.09 | 45.20 | 307,437 | 52.78 | 291.60% |
Nuvalent Description
| Nuvalent Inc is a biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. |
